Cytotoxicity Analysis Research Articles

Application of atmospheric cold plasma for zearalenone detoxification in cereals: Kinetics, mechanisms, and cytotoxicity analysis

IntroductionZearalenone (ZEN) is one of the most widely contaminated mycotoxins in world, posing a severe threat to human and animal health. Atmospheric cold plasma (ACP) holds great penitential in mycotoxin degradation. ObjectivesThis study aimed to investigate the degradation efficiency and mechanisms of ACP on ZEN as well as the cytotoxicity of ZEN degradation products by ACP. Additionally, this study also investigated the degradation efficiency of ACP on ZEN in cereals and its effect on cereal quality. MethodsThe degradation efficiency and products of ZEN by ACP was analyzed by HPLC and LC-MS/MS. The human normal liver cells and mice were employed to assess the cytotoxicity of ZEN degradation products. The ZEN artificially contaminated cereals were used to evaluate the feasibility of ACP detoxification in cereals. ResultsThe results showed that the degradation rate of ZEN was 96.18 % after 30-W ACP treatment for 180 s. The degradation rate was dependent on the discharge power, and treatment time and distance. Four major ZEN degradation products were produced after ACP treatment due to the oxidative destruction of CC double bond, namely C18H22O7 (m/z = 351.19), C18H22O8 (m/z = 367.14), C18H22O6 (m/z = 335.14), and C17H20O6 (m/z = 321.19). L02 cell viability was increased from 52.4 % to 99.76 % with ACP treatment time ranging from 0 to 180 s. Mice results showed significant recovery of body weight and depth of colonic crypts as well as mitigation of glomerular and liver damage. Additionally, ACP removed up to 50.55 % and 58.07 % of ZEN from wheat and corn. ConclusionsThis study demonstrates that ACP could efficiently degrade ZEN in cereals and its cytotoxicity was significantly reduced. Therefore, ACP is a promising effective method for ZEN detoxification in cereals to ensure human and animal health. Future study needs to develop large-scale ACP device with high degradation efficiency.

Analysis of Mycotoxins and Cytotoxicity of Airborne Molds Isolated from the Zoological Garden-Screening Research.

The objective of this paper was to assess the airborne mold contamination, secondary metabolite profiles, and cytotoxicity of the dominant fungal species isolated from the air in selected rooms at a Zoological Garden. Fungal concentrations were measured with MAS-100 air samplers. The collected airborne fungi were identified using a combination of morphological and molecular methods. The cytotoxicity of 84 strains belonging to two Penicillium and Aspergillus genera was determined using the quantitative colorimetric MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium salt) assay. The mycotoxins were detected using high-performance liquid chromatography (HPLC) with a mass spectrometry detector. The ITS gene was amplified and sequenced to identify the 132 species. For mycotoxicological and cytotoxicity analyses, 52 Penicillium isolates and 32 Aspergillus representatives were selected. Cytotoxicity was confirmed in 97.6% of cases analyzed. Using the LC-MS/MS method, 42 out of 84 strains produced at least one of the following toxins: ochratoxin A, ochratoxin B, patulin, gliotoxin, roquefortine C, griseofulvin, sterigmatocystin, fumonisin B2, moniliformin, and mycophenolic acid. Analytical methods for assessing the presence of mycotoxins in fungal isolates collected directly from the air have proven to be an effective tool. Our research provides new information on the occurrence of potentially toxin-producing molds within a zoo.

Synthesis, Characterization and Response of Newer Benzamidine Analogues against Porphyromonas gingivalis mediated Peri-Implantitis

Evidence suggests development of various therapeutic strategies against peri-implantitis ranging from plant extracts to synthetic molecules, but the development of resistance and associated side effects motivates the investigators to explore some new therapeutic moieties. Therefore, the present study was aimed to perform the synthesis, characterization, in vitro cytotoxicity analysis and in vitro antimicrobial activity of novel benzamidine analogues (NBA) against Porphyromonas gingivalis mediated peri-implantitis. To achieve the objectives of present study, 12 newer benzamidine analogues (NBA) were designed and subjected to molecular docking against Kgp-lysine specific cysteine proteinases gingipain K (PDB ID: 4RBM). Thus in present study, novel benzamidine analogues (NBA) were synthesized, followed by characterization (using attenuated total reflectance infrared, 1H & 13C NMR and direct infusion mass spectral data), in vitro antimicrobial activity (MIC and MBC) of NBA against P. gingivalis (using micro broth dilution method) and in vitro cytotoxicity analysis of NBA against HEK 293 cells (using MTT assay). The study offered successful synthesis of three NBA (3a-c) and elucidated their structures. All the synthesized NBA exhibited good antimicrobial activity against P. gingivalis with MIC value ranged between 31.25-250 µg/mL. Also, all NBA exhibited weak/negligible cytotoxicity against HEK 293 cells at 7.81 µg/mL. In conclusion, this study has led to the successful synthesis of effective peri-implantitis inhibitors with no significant toxicity. Present study recommends that, in future, the synthesized NBA should be further evaluated for their clinical importance in the peri-implantitis.

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

Pediatric high-grade gliomas (pHGGs), including diffuse midline gliomas (DMGs), are aggressive pediatric tumors with one of the poorest prognoses. Delta-24-RGD and ONC201 have shown promising efficacy as single agents for these tumors. However, the combination of both agents has not been evaluated. The production of functional viruses was assessed by immunoblotting and replication assays. The antitumor effect was evaluated in a panel of human and murine pHGG and DMG cell lines. RNAseq, the seahorse stress test, mitochondrial DNA content, and γH2A.X immunofluorescence were used to perform mechanistic studies. Mouse models of both diseases were used to assess the efficacy of the combination in vivo. The tumor immune microenvironment was evaluated using flow cytometry, RNAseq, and multiplexed immunofluorescence staining. The Delta-24-RGD/ONC201 combination did not affect the virus replication capability in human pHGG and DMG models in vitro. Cytotoxicity analysis showed that the combination treatment was either synergistic or additive. Mechanistically, the combination treatment increased nuclear DNA damage and maintained the metabolic perturbation and mitochondrial damage caused by each agent alone. Delta-24-RGD/ONC201 cotreatment extended the overall survival of mice implanted with human and murine pHGG and DMG cells, independent of H3 mutation status and location. Finally, combination treatment in murine DMG models revealed a reshaping of the tumor microenvironment to a proinflammatory phenotype. The Delta-24-RGD/ONC201 combination improved the efficacy compared to each agent alone in in vitro and in vivo models by potentiating nuclear DNA damage and in turn improving the antitumor (immune) response to each agent alone.

Chemotherapeutic prospects of organic extracts of Bornetella nitida from Selayar Island

In this study, we aimed to identify the chemotherapeutic potential of Bornetella nitida, a Dasycladacean that contains various phytochemicals. Phytochemical extraction was performed using gradient maceration with n-hexane, chloroform, ethyl acetate, and methanol. Additionally, toxicity tests as well as antioxidant activity, cytotoxicity, phytochemical, and molecular docking analyses against three main cervical cancer proteins were performed. The B. nitida extracts showed moderate toxicity with LC50 ranging from 116.06 to 713.12 μg mL−1. The free-radical scavenging activity of 2,2-diphenyl-1-picrylhydrazyl varied with solvent polarity, exhibiting IC50 values of 22.20, 87.77, 401.55, and 752.08 μg mL−1 when extracted using n-hexane, chloroform, ethyl acetate, and methanol, respectively. Meanwhile, the cytotoxicity against HeLa cells ranged from 281.09 to 1329.33 μg mL−1, with the highest activity shown by the ethyl acetate extract. Gas chromatography-mass spectrometry (GC-MS) analysis revealed the presence of phytochemicals with various bioactivities in the extract, such as L-ascorbic acid 2,6-dihexadecanoate, octadec-9-enoic acid, hexadecatrienoic acid, 2,4-bis(1,1-dimethylethyl)phenol, 9,12-octadecadienoic acid (Z,Z), 1,2-benzenedicarboxylic acid, 2,6,10-trimethyl-14-ethylene-14-pentadecene, and phytol. Docking studies implied that the compounds commonly interact well with the binding site of the target protein. Overall, our results indicate that B. nitida extracts especially ethyl acetate extract can be developed as chemotherapeutic agents.

Green Synthesis of Cobalt Oxide Nanoparticles with In-vitro Cytotoxicity Assessment Using Pomegranate (Punica granatum L.) Seed Oil: A Promising Approach for Antimicrobial and Anticancer Applications

Green synthesis of nanoparticles and their pharmacological implementation have gained importance in the field of nanotechnology. This study primarily aims to explore the use of Punica granatum L. seed oil as a reducing agent for the synthesis of cobalt nanoparticles, making it both economically and pharmacologically valuable. Gas chromatography-mass spectroscopy analysis was carried out to study the active metabolites present in P. granatum seed oil. The green synthesis of cobalt nanoparticles was established based on the color change of the reaction mixture from dark green to light green. These particles showed a ?max at 279.88 nm for UV-visible spectrometry analysis. Furthermore, X-ray Diffraction (XRD), Fourier Transform Infrared Spectroscopy (FTIR), Field Emission Scanning Electron Microscope (FE SEM) and Dynamic Light Scattering (DLS) were performed to confirm the nature of these nanoparticles. The pharmacological potential of these cobalt oxide nanoparticles was tested against microbial pathogens. The results suggest that these nanoparticles exhibited significant activity against various human bacterial and fungal pathogens. Additionally, in in vitro cytotoxicity analysis, demonstrated that CoONPs selectively targeted MCF-7 cancer cells with a significant IC50 value compared to non-cancerous cells (L929). In conclusion, this study demonstrated that green synthesized CoONPs using P. granatum show significant potential against eukaryotic cancer cells and microbial pathogens. Furthermore, this study has implications for medical research centers and pharmaceutical industries in addressing modern challenges such as increasing antibiotic resistance in communities.

Uncontrolled Post-Industrial Landfill-Source of Metals, Potential Toxic Compounds, Dust, and Pathogens in Environment-A Case Study.

The aim of this case study was the evaluation of the selected metals' concentration, potential toxic compound identification, cytotoxicity analysis, estimation of the airborne dust concentration, biodiversity, and number of microorganisms in the environment (leachate, soil, air) of the biggest uncontrolled post-industrial landfills in Poland. Based on the results obtained, preliminary solutions for the future management of post-industrial objects that have become an uncontrolled landfill were indicated. In the air, the PM1 fraction dominated, constituting 78.1-98.2% of the particulate matter. Bacterial counts were in the ranges of 9.33 × 101-3.21 × 103 CFU m-3 (air), 1.87 × 105-2.30 × 106 CFU mL-1 (leachates), and 8.33 × 104-2.69 × 106 CFU g-1 (soil). In the air, the predominant bacteria were Cellulosimicrobium and Stenotrophomonas. The predominant fungi were Mycosphaerella, Cladosporium, and Chalastospora. The main bacteria in the leachates and soils were Acinetobacter, Mortierella, Proteiniclasticum, Caloramator, and Shewanella. The main fungi in the leachates and soils were Lindtneria. Elevated concentrations of Pb, Zn, and Hg were detected. The soil showed the most pronounced cytotoxic potential, with rates of 36.55%, 63.08%, and 100% for the A-549, Caco-2, and A-549 cell lines. Nine compounds were identified which may be responsible for this cytotoxic effect, including 2,4,8-trimethylquinoline, benzo(f)quinoline, and 1-(m-tolyl)isoquinoline. The microbiome included bacteria and fungi potentially metabolizing toxic compounds and pathogenic species.

Network pharmacology and experimental insights into STAT3 inhibition by novel isoxazole derivatives of piperic acid in triple negative breast cancer

STAT3 is a crucial member within a family of seven essential transcription factors. Elevated STAT3 levels have been identified in various cancer types, notably in breast cancer (BC). Consequently, inhibiting STAT3 is recognized as a promising and effective strategy for therapeutic intervention against breast cancer. We herein synthesize a library of isoxazole (PAIs) from piperic acid [2E, 4E)-5-(2H-1,3-Benzodioxol-5-yl) penta-2,4-dienoic acid] on treatment with propargyl bromide followed by oxime under prescribed reaction conditions. Piperic acid was obtained by hydrolysis of piperine extracted from Piper nigrum. First, we checked the binding potential of isoxazole derivatives with breast cancer target proteins by network pharmacology, molecular docking, molecular dynamic (MD) simulation and cytotoxicity analysis as potential anti-breast cancer (BC) agents. The multi-source databases were used to identify possible targets for isoxazole derivatives. A network of protein-protein interactions (PPIs) was generated by obtaining 877 target genes that overlapped gene symbols associated with isoxazole derivatives and BC. Molecular docking and MD modelling demonstrated a strong affinity between isoxazole derivatives and essential target genes. Further, the cell viability studies of isoxazole derivatives on the human breast carcinoma cell lines showed toxicity in all breast cancer cell lines. In summary, our study indicated that the isoxazole derivative showed the significant anticancer activity. The results highlight the prospective utility of isoxazole derivatives as new drug candidates for anticancer chemotherapy, suggesting route for the continued exploration and development of drugs suitable for clinical applications.

Single-cell transcriptional signature-based drug repurposing and in vitro evaluation in colorectal cancer

BackgroundThe need for intelligent and effective treatment of diseases and the increase in drug design costs have raised drug repurposing as one of the effective strategies in biomedicine. There are various computational methods for drug repurposing, one of which is using transcription signatures, especially single-cell RNA sequencing (scRNA-seq) data, which show us a clear and comprehensive view of the inside of the cell to compare the state of disease and health.MethodsIn this study, we used 91,103 scRNA-seq samples from 29 patients with colorectal cancer (GSE144735 and GSE132465). First, differential gene expression (DGE) analysis was done using the ASAP website. Then we reached a list of drugs that can reverse the gene signature pattern from cancer to normal using the iLINCS website. Further, by searching various databases and articles, we found 12 drugs that have FDA approval, and so far, no one has reported them as a drug in the treatment of any cancer. Then, to evaluate the cytotoxicity and performance of these drugs, the MTT assay and real-time PCR were performed on two colorectal cancer cell lines (HT29 and HCT116).ResultsAccording to our approach, 12 drugs were suggested for the treatment of colorectal cancer. Four drugs were selected for biological evaluation. The results of the cytotoxicity analysis of these drugs are as follows: tezacaftor (IC10 = 19 µM for HCT-116 and IC10 = 2 µM for HT-29), fenticonazole (IC10 = 17 µM for HCT-116 and IC10 = 7 µM for HT-29), bempedoic acid (IC10 = 78 µM for HCT-116 and IC10 = 65 µM for HT-29), and famciclovir (IC10 = 422 µM for HCT-116 and IC10 = 959 µM for HT-29).ConclusionsCost, time, and effectiveness are the main challenges in finding new drugs for diseases. Computational approaches such as transcriptional signature-based drug repurposing methods open new horizons to solve these challenges. In this study, tezacaftor, fenticonazole, and bempedoic acid can be introduced as promising drug candidates for the treatment of colorectal cancer. These drugs were evaluated in silico and in vitro, but it is necessary to evaluate them in vivo.

Synthesis and Validation of TRIFAPYs as a Family of Transfection Agents for Therapeutic Oligonucleotides.

Transfection agents play a crucial role in facilitating the uptake of nucleic acids into eukaryotic cells offering potential therapeutic solutions for genetic disorders. However, progress in this field needs the development of improved systems that guarantee efficient transfection. Here, we describe the synthesis of a set of chemical delivery agents (TRIFAPYs) containing alkyl chains of different lengths based on the 1,3,5-tris[(4-alkyloxy-1pyridinio)methyl]benzene tribromide structure. Their delivery properties for therapeutic oligonucleotides were evaluated using PolyPurine Reverse Hoogsteen hairpins (PPRHs) as a silencing tool. The binding of liposomes to PPRHs was evaluated by retardation assays in agarose gels. The complexes had a size of 125 nm as determined by DLS, forming well-defined concentrical vesicles as visualized by Cryo-TEM. The prostate cancer cell line PC-3 was used to study the internalization of the nanoparticles by fluorescence microscopy and flow cytometry. The mechanism of entrance involved in the cellular uptake was mainly by clathrin-mediated endocytosis. Cytotoxicity analyses determined the intrinsic toxicity caused by each TRIFAPY and the effect on cell viability upon transfection of a specific PPRH (HpsPr-C) directed against the antiapoptotic target survivin. TRIFAPYs C12-C18 were selected to expand these studies in the breast cancer cell line SKBR-3 opening the usage of TRIFAPYs for both sexes and, in the hCMEC/D3 cell line, as a model for the blood-brain barrier. The mRNA levels of survivin decreased, while apoptosis levels increased upon the transfection of HpsPr-C with these TRIFAPYs in PC-3 cells. Therefore, TRIFAPYs can be considered novel lipid-based vehicles for the delivery of therapeutic oligonucleotides.

Tuning The physicochemical Properties of CeO2 Nanoparticles for Enhanced Photocatalytic and Anticancer Performance by Zn Doping

Semiconductor nanoparticles (NPs) have attracted considerable attention owing to their potential applications, such as optoelectronic devices, environmental remediation, energy conversion, and biomedical. This work was designed to tailor the physicochemical properties of CeO2 NPs by Zn doping at different concentrations (0 ≤ x ≤ 0.03) to improve their photocatalytic and anticancer performance. The modified co-precipitation route was fruitfully applied to prepare ZnxCe1-xO2 NPs (with 0 ≤ x ≤ 0.03). Different characterization facilities like XRD, TEM, SEM, EDX, FTIR, and PL spectroscopy have been employed to examine the properties of these prepared NPs. XRD data revealed that the crystallite of NPs was changed after Zn doping with the decrease of its crystal sizes. TEM and SEM imaging discovered that the NPs were further sphere-shaped with homogenous distribution. Moreover, SEM elemental mapping with EDX confirmed that the elements (Ce, O, and Zn) in prepared NPs have uniform distribution and chemical composition in prepared Zn0·03Ce0·97O2 NPs. FTIR results determined the functional groups in the prepared NPs. PL spectra observed a decrease in the recombination of electron (e−)-hole (h+) pair with increasing Zn doping due to a change in bandgap energy. Photocatalytic data indicates that the photodegradation efficiency (D) of Rh B dye of Zn0·03Ce0·97O2NPs(75.5%) under UV light during 100 min was greater than pure CeO2 NPs. Cytotoxicity analysis showed that the anticancer effect of CeO2 NPs against human liver cancer (HepG2) increases with the addition of Zn ions. Additionally, these results indicated that the addition of Zn ions to CeO2 NPs plays a role in killing cancer cells at higher concentrations. This study recommended that these NPs could be applied to potential applications in environmental pollution and cancer therapy in vivo studies.

Prebiotic levan type fructan from Bacillus subtilis PR-C18 as a potent antibiofilm agent: Structural elucidation and in silico analysis

The global demand for therapeutic prebiotics persuades the quest for novel exopolysaccharides that can retard the growth of pathobionts and healthcare-associated pathogens. In this regard, an exopolysaccharide (3.69 mg/mL) producing strain showing prebiotic and antibiofilm activity was isolated from indigenous pineapple pomace of Tripura and identified as Bacillus subtilis PR-C18. Zymogram analysis revealed EPS PR-C18 was synthesized by levansucrase (∼57 kDa) with a maximal activity of 4.62 U/mg. Chromatography techniques, FTIR, and NMR spectral data revealed the homopolymeric nature of purified EPS with a molecular weight of 3.40 × 104 Da. SEM and rheological study unveiled its microporous structure and shear-thinning effect. Furthermore, EPS PR-C18 showed remarkable emulsification, flocculation, water retention, water solubilization, and antioxidant activity. DSC-TGA data demonstrated its high thermostability and cytotoxicity analysis verified its nontoxic biocompatible nature. In addition, the antibiofilm activity of EPS PR-C18 was validated using molecular docking, molecular simulation, MM-GBSA and PCA studies, which exhibited its strong binding affinity (−20.79 kcal/moL) with PelD, a virulence factor from Pseudomonas aeruginosa. Together, these findings support the future exploitation of EPS PR-C18 as an additive or adjuvant in food and pharmaceutical sectors.

Abstract 7255: Peptide-based siRNA delivery for tumor-specific targeting of lactate dehydrogenase C

Abstract Background: Breast cancer is the most common cancer worldwide and the leading cause of female cancer-related deaths, highlighting the pressing need for novel therapeutic interventions. Treatment of triple negative breast cancer in particular remains a challenge due to disease aggressiveness and the lack of durable treatment options. We speculate that targeting of Lactate Dehydrogenase C (LDHC) could be a novel approach given its highly tumor specific expression and immunogenic properties. We recently demonstrated that LDHC acts as a key regulator of the DNA damage response and tumor mitotic fidelity. Moreover, silencing of LDHC significantly improved treatment response to DNA damage response related anti-cancer drugs, highlighting its therapeutic potential for cancer precision medicine. Methods: We characterized and evaluated several cell penetrating peptide-siRNA complexes for efficient silencing of LDHC in tumor cells using a 10R polyarginine peptide or bifunctional 10R-RGD, cRGD-10R or iRGD-10R peptides with tumor homing and penetrating abilities. Results: Peptide-siRNA complex formation and tumor cellular uptake was confirmed using gel retardation assays and fluorescent confocal imaging. Biophysiochemical characterization and transmission electron microscopy revealed the complexes to be uniform in size with a low polydispersity index and positive zeta potentials. LDHC silencing in breast cancer cells using the peptide complexes demonstrated a 30-53% reduction in LDHC expression, with the 10R-siRNA and cRGD-10R-siRNA complexes showing the highest silencing efficiency. In 3D breast cancer spheroids, transfection with the 10R-siRNA complex resulted in a 20% downregulation of LDHC expression. Further analysis of the bifunctional-siRNA complexes in 3D cultures is ongoing as well as cytotoxicity analyses on non-cancerous cell lines. Conclusions: Our findings demonstrate that peptide-mediated delivery of LDHC siRNA can reduce LDHC expression in 2D and 3D breast cancer cultures, suggesting that they could be used as a valuable approach for therapeutic intervention. Citation Format: Adviti Naik, Hanan Qasem, Julie Decock. Peptide-based siRNA delivery for tumor-specific targeting of lactate dehydrogenase C [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7255.

Preparation, characterization and cytotoxicity assessment of a novel selenized polysaccharide from Morchella sextelata

Selenylation modification has been widely developed to improve the biological effects of natural polysaccharides. In this study, a purified new polysaccharide (MSP-4) was isolated from Morchella Sextelata, and selenized into SeMSP-4 using the HNO3-Na2SeO3 method. The selenium (Se) content of SeMSP-4 was 101.81 ± 9.90 mg/kg, and the molecular weight of SeMSP-4 was 1.23 × 105 Da. The FT-IR, XRD and AFM results showed that MSP-4 was successfully combined with the Se element. The structure characters of SeMSP-4 were analyzed by methylation analysis combined with 1D and 2D NMR spectroscopy. And, the radical scavenging test revealed that SeMSP-4 exhibited higher antioxidant capacities in vitro than MSP-4. The cytotoxicity analysis indicated that SeMSP-4 could dose-dependently inhibit the proliferation of HepG2 and HeLa cells, but did not show a cytotoxic effect on normal cells (HEK293). Furthermore, SeMSP-4 stimulation significantly increased the macrophage viability and enhanced NO production in macrophage cells. This study suggested that SeMSP-4 could be utilized as a potential selenium source with antioxidant, antitumor, and immunostimulatory activities.

Abstract 7496: The piritramide-based perioperative analgesia can affect the cancer dissemination in colorectal cancer patients

Abstract Introduction: Colorectal cancer (CRC) stands as a prominent contributor to global cancer-related mortality. Post-surgical management of CRC patients often involves the administration of opioid analgesics. These analgesics operate through opioid and cannabinoid receptors, pathways implicated in tumor progression and metastasis, potentially impacting patient survival adversely. This investigation delves into the influence of piritramide and morphine on cancer dissemination, encompassing in vitro and in vivo assessments, cytotoxicity analyses, and elucidation of their mode of action. Methods: The presence of circulating tumor cells (CTCs) in the blood of 131 CRC patients was quantitatively assessed using the real-time polymerase chain reaction (qPCR) method. Cytotoxic effects of morphine and piritramide were evaluated via colony-forming assays (CFA) utilizing HCT116 and HT29 cell lines. The impact of piritramide and morphine on opioid receptor activity was gauged through transfected reporter cell lines and fluorescence imaging plater reader (FLIPR) calcium assays. In vivo models involving subcutaneous and intrasplenic administration in SCID and BALB mice, respectively, utilizing HCT116 and HT29 cell lines, were conducted. Morphological profiling, employing the cell painting assay, facilitated high-content image-based analysis on both cell lines. Results: Perioperative analgesia with piritramide exhibited a tendency towards longer time to recurrence (TTR) survival in CRC patients (HR=1.8, p=0.104). Conversely, morphine-treated patients demonstrated a twofold increase in TTR events (HR=4.7, p=0.011). Piritramide, but not morphine, significantly inhibited colony growth in HCT116 and HT-29 cell lines in the CFA, consistent with cytotoxicity test results. Functional assays revealed agonistic effects of both piritramide and morphine on opioid receptor kappa 1 (OPRK1) and mu 1 (OPRM1), with piritramide exhibiting greater potency as an OPRK1 agonist. In the SCID mice model, subcutaneous application of HT29 cell lines resulted in significantly reduced tumor growth in piritramide-treated mice. In the intrasplenic model utilizing BALB mice, mice treated with piritramide exhibited diminished tumor growth and a reduction in both the number and size of metastases. Comparative analysis with reference compounds revealed a distinct phenotypic profile of piritramide affecting the endoplasmic reticulum. Conclusion: Piritramide, as opposed to morphine, demonstrated cytotoxic effects on both in vitro and in vivo CRC cell lines, resulting in reduced tumor growth and dissemination. Perioperative analgesia with piritramide exhibited potential in improving time to recurrence survival in CRC patients. Acknowledgement: This study received support from the European Union - Next Generation EU (LX22NPO5102) and Palacky University Olomouc (LF 2023_006). Citation Format: Josef Srovnal, Emil Berta, Monika Vidlarova, Alona Rehulkova, Katerina Jecmenova, Miroslav Popper, Alzbeta Srovnalova, Petr Prasil, Pavel Skalicky, Tomas Gabrhelik, Jan Maca, Pavel Michalek, Marian Hajduch. The piritramide-based perioperative analgesia can affect the cancer dissemination in colorectal cancer patients [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 7496.

Abstract 4546: Pegargiminase and melphalan as a novel drug combination strategy for uveal melanoma

Abstract Uveal melanoma (UM) is a hard-to-treat arginine auxotrophic cancer with approximately 50% of patients succumbing to metastases predominantly to the liver with a median overall survival of 19-22 months and a 5 year survival of around 10%. Novel drug strategies are urgently needed beyond the currently available immunotherapies that provide durable disease control in a small subset of patients. Arginine deprivation with pegylated arginine deiminase (ADI-PEG20; pegargiminase) is a novel anti-metabolite therapy which demonstrated activity in early phase trials in patients with UM, and more recently, increased survival in patients with the aggressive arginine-dependent cancer, non-epithelioid mesothelioma in the global phase 3 trial, ATOMIC-Meso. Here, we investigated the preclinical rationale for combining pegargiminase with melphalan, a drug which is delivered directly to the liver using an FDA-approved device from Delcath for patients with hepatic-centric UM disease. Two of four uveal melanoma cell lines were negative for expression of the rate-limiting enzyme for arginine production, argininosuccinate synthetase 1 (ASS1) and were submitted for drug evaluation accordingly. ADI-PEG20 treatment of ASS1-deficient cell lines 91.2 and MP41 demonstrated sensitivity to ADI-PEG20 (500ng/ml) compared to MP38 and MP46 ASS1-proficient cell lines. Moreover, the combination of ADI-PEG20 and melphalan (0.77µM) had at least an additive effect on ASS1 negative cell lines in 2D assay (92.1 p-value 0.0061; MP41 p-value is 0.0053). UM cell line proliferation was decreased by 50% in the combination group compared to ADI-PEG20 alone by 6 days of culture. Experiments to assess cytotoxicity and cell death analysis are ongoing. This drug combination therapy has the potential to improve outcomes in patients with uveal melanoma. Based on the good tolerability and safety of both drugs in patients, a clinical trial of pegargiminase with melphalan is planned for 2024 (ATOMIC-UM). Citation Format: Iuliia Pavlyk, Josephine Carpentier, Emilia Appolonia Szlosarek, Pui Ying Chan, John S. Bomalaski, Peter Wojciech Szlosarek. Pegargiminase and melphalan as a novel drug combination strategy for uveal melanoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4546.

Abstract 5117: CK2 inhibiton exhibits synergistic effect in acute lymphoblastic leukemia

Abstract Survival for pre-B cell Acute lymphoblastic leukemia (B ALL) has improved greatly, however. High risk (HR) subgroups continue to result in significant mortality and morbidity of pediatric oncology patients. Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is a lethal disease, often associated with high-risk clinical features. T-ALL therapy has made less improvement than B ALL and continues to represent a significant number of high-risk outcomes. Novel treatment strategies are required to overcome chemotherapy resistance and improve morbidity for HR B ALL. The development of treatments that can overcome chemotherapy resistance is essential for improving survival in T-ALL. Deletions of IKZF1, resulting in decreased IKAROS function, are present in High-risk ALL patients. Casein kinase 2 (CK2), a protein kinase upregulated in ALL, phosphorylates IKAROS preventing DNA binding reducing transcriptional regulation in ALL patients. Past studies have shown that pharmacologic inhibition of CK2 with CX-4945 rescues IKAROS function as a transcriptional regulator. Receptor tyrosine kinase c-KIT is transcriptionally regulated by IKAROS and is often upregulated in cancer. The purpose of this study was to determine whether restoration of IKAROS via CX-4945 would act in a synergistic manner with c-KIT inhibitor imatinib in ALL.Methods/results B-ALL Nalm6 cells were treated with imatinib over 72-hours to establish the half-maximal inhibitory concentration (IC50). The IC50 was used to determine the concentration range of imatinib to be used in combination with CX-4945 in a 72-hour synergy analysis of cytotoxicity.. Cell viability was measured using WST-1 cell proliferation assay. The data were analyzed using Calcusyn and synergy was defined as a combination index below 0.85. The study was repeated to determine a more precise range of synergy. The cytotoxicity of single drug c-KIT inhibitor, Imatinib, in Nalm6 B-ALL yielded an IC50 of 25uM while CK2 inhibitor CX-4945 resulted in 4uM. When a combination was administered with a constant dose of CX-4945 at 4uM and varying concentrations of imatinib, synergy was observed at multiple dose combinations. Conclusion: The data shows that CK2 inhibitor, CX-4945, and c-KIT inhibitor, imatinib, exhibit a synergistic therapeutic effect. Imatinib is indicated for use in Philadelphia positive (Ph+) acute lymphoblastic leukemia so future studies will include testing CX-4945/imatinib synergy in Ph+ BALL where we expect to see more potent synergistic effect. Citation Format: Daniel Gary Bogush, Joseph Schramm, Katarina Dovat, Yali Ding, Chingakham Singh, Sinisa Dovat. CK2 inhibiton exhibits synergistic effect in acute lymphoblastic leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 5117.

Design, synthesis, and biological evaluation of eugenol-isoxazoline hybrid derivatives as potential anti-leishmanial agents

Leishmaniasis is a group of protozoan parasitic diseases caused by various Leishmania species. The clinical manifestations range from skin abrasions to lethal infection in the visceral organs such as the liver and spleen. The emergence of drug resistance, long hospitalization periods, and various adverse effects of the current therapeutic regimen have incited the quest for exploring novel molecules as efficient treatment regimens. Eugenol is the major component of clove essential oil and has significant biological potential with anti-microbial properties. Moreover, natural product derivatives having the isoxazoline group have shown promising pharmacological applications. Thus, various analogs were synthesized and characterized to explore the anti-leishmanial potency of eugenol and isoxazoline hybrid. Results from the in vitro assay against Leishmania donovani parasites identified three potent derivatives (7e, 8a, and 8b) with IC50 values in the range of 7–17 µM. Cytotoxicity analysis against the J774A.1 macrophage cell line confirmed the satisfactory safety index of these potent hits and ex vivo infectivity assay established the role of these hits in reducing intracellular amastigote burden. Next, various mechanistic studies, including SEM analysis, higher ROS production, reduced intracellular ATP levels, mitochondrial dysfunction, formation of intracellular lipid bodies, and acidic vesicular organelles, confirmed the role of these potent hits in parasite cell death. According to the molecular docking analysis results, the most potent derivative, 8b, had strong binding interactions with residues Ile296, Pro299, and Phe354 of sterol 14α-demethylase protein of the Leishmania parasite. Entirely the study highlights the role of eugenol-isoxazoline hybrid derivatives as potential leishmanicidal agents.

Optimization and analysis of sustainable magnesium-based alloy (Mg-Zn-Ca-Y) for biomedical applications

Due to strength and biodegradability, magnesium (Mg) and its alloys are potential biodegradable implant materials. However, pure Mg corrodes more rapidly in the physiological environment, causing rapid deterioration before bone repair. The discrepancy between bone healing and Mg implant deterioration encourages the development of new Mg alloys with other acceptable alloying elements to achieve the desired high corrosion resistance and mechanical properties. In this work, different concentrations of yttrium (Y), that is, Mg-4zn-0.2ca-xY, (x= 3,6,9,12% wt), are added to Mg-based alloys. The microstructure, mechanical characteristics, corrosion behavior, and biocompatibility of the alloys were carefully investigated. When Y concentrations are high, Mg alloys with Y change significantly. High Y concentrations in Mg alloys containing yttrium (Y) suppress intermetallic phases along grain boundaries and form chemically stable Y oxide layers on the surfaces, changing their microstructures and improving their corrosion resistance. Cytotoxicity analysis showed that human osteoblast cells were not significantly affected by the Y-containing Mg alloys. The benefits of using Y as an alloying element to simultaneously adjust Mg alloys with higher strength and slower deterioration are presented.

Evaluating synergistic effects of metformin and simvastatin on ovarian cancer cells.

Ovarian Cancer (OC) stands as the most lethal gynecological malignancy, presenting an urgent clinical challenge in the quest to improve response rates. One approach to address this challenge is through drug repurposing, exemplified by the investigation of metabolic-modulating drugs such as Metformin (MTF) and Simvastatin (SIM). This study aims to explore the molecular mechanisms contributing to the potential synergistic anti-cancer effects between MTF and SIM on ovarian cancer cells. We assessed the effects of the combination on the proliferation and viability of two cell lines OVCAR-3 and SKOV-3. IC50 concentrations of MTF and SIM were determined using a proliferation assay, followed by subtoxic concentrations to explore the potential synergistic effects on the viability of both cell lines. Transcriptomic analysis was conducted on OVCAR-3 treated cells, and the findings were validated by assessing the expression levels of differentially expressed genes (DEGs) through real-time PCR in both cell lines SK-OV-3 and OVCAR-3. Cytotoxicity analysis guided the selection of treatment concentrations as such MTF 10 mM and SIM 5 μM. The combined treatment of MTF and SIM demonstrated a synergistic inhibition of proliferation and viability in both cell lines. In OVCAR-3, exclusive identification of 507 DEGs was seen in the combination arm. Upregulation of FOXO3, RhoA, and TNFα, along with downregulation of PIK3R1, SKP2, and ATP6V1D levels, was observed in OVCAR-3 treated cells. Real-time PCR validation confirmed the consistency of expression levels for the mentioned DEGs. Our data strongly supports the presence of synergy between MTF and SIM in OC cells. The combination's effect is associated with the dysregulation of genes in the key regulators AMPK and mTOR alongside other interconnected pathways.